Cargando…

Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report

BACKGROUND: Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Shimizu, Kazuhiro, Sasaki, Takeshi, Tomaru, Takanobu, Noike, Hirofumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962499/
https://www.ncbi.nlm.nih.gov/pubmed/27468257
http://dx.doi.org/10.1186/s12959-016-0089-x
_version_ 1782444849409032192
author Shimizu, Kazuhiro
Sasaki, Takeshi
Tomaru, Takanobu
Noike, Hirofumi
author_facet Shimizu, Kazuhiro
Sasaki, Takeshi
Tomaru, Takanobu
Noike, Hirofumi
author_sort Shimizu, Kazuhiro
collection PubMed
description BACKGROUND: Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We present a case of extensive deep vein thrombosis treated using fondaparinux and edoxaban. CASE PRESENTATION: A 63-year-old man with redness, pain, and swelling of the left leg lasting for more than 1 month was referred to our hospital. Ultrasonography revealed a thrombus in the left femoral vein. Computed tomographic angiography revealed clots in the distal right pulmonary artery. Thus, the anticoagulant treatment was initiated with subcutaneous injections of fondaparinux (7.5 mg) for 5 consecutive days, followed by once daily oral administration of edoxaban (60 mg). After 3 months of treatment, a regression of thrombotic clots was shown. Three months later, the remaining clots disappeared, leaving only mural thrombi; no bleeding complications were observed during the treatment period. CONCLUSION: The anticoagulant treatment with subcutaneous fondaparinux and subsequently with oral edoxaban was effective for treating extensive deep vein thrombosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12959-016-0089-x) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4962499
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-49624992016-07-28 Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report Shimizu, Kazuhiro Sasaki, Takeshi Tomaru, Takanobu Noike, Hirofumi Thromb J Case Report BACKGROUND: Factor Xa inhibitor is a key drug in the coagulation cascade. Parenteral anticoagulation using low molecular weight heparin or fondaparinux is the recommended form of treatment for most patients presenting with venous thrombosis. Following the acute phase, edoxaban is recommended. We present a case of extensive deep vein thrombosis treated using fondaparinux and edoxaban. CASE PRESENTATION: A 63-year-old man with redness, pain, and swelling of the left leg lasting for more than 1 month was referred to our hospital. Ultrasonography revealed a thrombus in the left femoral vein. Computed tomographic angiography revealed clots in the distal right pulmonary artery. Thus, the anticoagulant treatment was initiated with subcutaneous injections of fondaparinux (7.5 mg) for 5 consecutive days, followed by once daily oral administration of edoxaban (60 mg). After 3 months of treatment, a regression of thrombotic clots was shown. Three months later, the remaining clots disappeared, leaving only mural thrombi; no bleeding complications were observed during the treatment period. CONCLUSION: The anticoagulant treatment with subcutaneous fondaparinux and subsequently with oral edoxaban was effective for treating extensive deep vein thrombosis. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12959-016-0089-x) contains supplementary material, which is available to authorized users. BioMed Central 2016-07-27 /pmc/articles/PMC4962499/ /pubmed/27468257 http://dx.doi.org/10.1186/s12959-016-0089-x Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Shimizu, Kazuhiro
Sasaki, Takeshi
Tomaru, Takanobu
Noike, Hirofumi
Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
title Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
title_full Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
title_fullStr Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
title_full_unstemmed Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
title_short Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
title_sort extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4962499/
https://www.ncbi.nlm.nih.gov/pubmed/27468257
http://dx.doi.org/10.1186/s12959-016-0089-x
work_keys_str_mv AT shimizukazuhiro extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport
AT sasakitakeshi extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport
AT tomarutakanobu extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport
AT noikehirofumi extensivedeepveinthrombosistreatmentusingfondaparinuxandedoxabanacasereport